TY - JOUR T1共病对中国1590例COVID-19患者的影响:全国分析JF -欧洲呼吸杂志》乔和J - 10.1183/13993003.00547 -2020欧元六世- 55 - 5 SP - 2000547 AU关Wei-jie AU -梁,文非盟——赵,易盟——梁、Heng-rui AU - Chen Zi-sheng AU - Li Yi-min盟——刘Xiao-qing AU - Chen Ru-chong AU - Tang春丽AU -王,道盟——或者,Chun-quan AU -李,李盟——陈Ping-yan盟——唱,凌AU -王,李魏盟——Jian-fu AU - Li Cai-chen盟——或者,李敏AU - Cheng博盟——熊,掸族盟——倪,Zheng-yi盟——湘杰盟——胡余盟——刘,Lei盟——山,香港非盟- Lei, Chun-liang盟——彭Yi-xiang盟——魏、李盟——刘,永盟——胡Ya-hua盟——彭,彭AU - Wang Jian-ming盟——刘Ji-yang AU -陈,中盟-李,帮派盟——郑Zhi-jian盟——秋,Shao-qin AU -罗,杰盟——你们,长江三峡盟——朱Shao-yong AU - Cheng Lin-ling盟——你们冯AU - Li Shi-yue AU -郑,《金瓶梅盟——张Nuo-fu盟——钟,南山盟——他,Jian-xing A2 -,摘要N2 -背景2019冠状病毒病(COVID-19)疫情在全球范围内迅速发展。目的通过对COVID-19共病情况的分层分析，评估COVID-19患者发生严重不良反应的风险。方法我们分析了中国大陆31个省/自治区/直辖市575家医院的1590例实验室确诊的住院患者的数据，这些患者来自2019年12月11日至2020年1月31日。我们分析了复合终点，包括进入重症监护病房，有创通气或死亡。根据共病的存在和数量比较到达复合终点的风险。结果平均年龄48.9岁，女性686例(42.7%)。重症患者占研究人群的16.0%。131例(8.2%)患者达到复合终点。399(25.1%)报告有至少一种合并症。 The most prevalent comorbidity was hypertension (16.9%), followed by diabetes (8.2%). 130 (8.2%) patients reported having two or more comorbidities. After adjusting for age and smoking status, COPD (HR (95% CI) 2.681 (1.424–5.048)), diabetes (1.59 (1.03–2.45)), hypertension (1.58 (1.07–2.32)) and malignancy (3.50 (1.60–7.64)) were risk factors of reaching the composite end-points. The hazard ratio (95% CI) was 1.79 (1.16–2.77) among patients with at least one comorbidity and 2.59 (1.61–4.17) among patients with two or more comorbidities.Conclusion Among laboratory confirmed cases of COVID-19, patients with any comorbidity yielded poorer clinical outcomes than those without. A greater number of comorbidities also correlated with poorer clinical outcomes.The presence and number of comorbidities predict clinical outcomes of COVID-19 http://bit.ly/3b9ibw5 ER -